Clinical Trials › NCT07321093
RecruitingPhase 3
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Sponsored by Biocad
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 292
Target enrollment
Nov 2025
Start date
Dec 2028
Expected completion
Interventions / Treatments
BCD-281Ocrelizumab
Conditions studied
Relapsing-remitting Multiple Sclerosis (RRMS)
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.